Finally, to compare this assay across prostate cancer cell lines, the ability of Hsp90 inhibitors to inhibit luciferase refolding was examined in an LNCaP-LN3 luciferase expressing cell line (Figure 6D). Here, HSP90AA1 is linked to prostate cancer.